anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Described herein are diuretic condensation aerosols and methods of making and using them. Kits for delivering a condensation aerosol are also described. The diuretic aerosols typically comprise diuretic condensation aerosol particles that comprise a diuretic compound. In some variations the diuretic compound is selected from the group consisting of bumetanide, ethacrynic acid, furosemide, muzolimine, spironolactone, torsemide, triamterene, tripamide, BG 9928, and BG 9719. Methods of treating edema using the described aerosols are also provided. In general, the methods typically comprise the step of administering a therapeutically effective amount of diuretic condensation aerosol to a person with edema. The diuretic condensation aerosol may be administered in a single inhalation, or may be administered in more than one inhalation. Methods of forming a diuretic condensation aerosol are also described. The methods typically comprise the steps of providing a diuretic composition, vaporizing the composition to form a vapor, and then condensing the diuretic composition vapor.
A fatty acid based composition for treatment and/or prevention of enveloped-virus related infections by administering fatty acid based compositions. The present invention further provides a free fatty acid based sprayable composition to prevent and/or treatment of SARS-Virus related infections. The fatty acids used in the present invention are Linoleic acid (LA), α-linolenic acid (ALA) and gamma-linolenic acid (GLA). In a preferred embodiment, we propose that topical administration of naturally occurring fatty acids in an optimal formulation may be beneficial in the prophylaxis of respiratory enveloped viruses and in particular the lipid-rich SARS-CoV-2 virus. This could be administered via nasal and/or oral route. The composition comprises at least one fatty acid, a suitable carrier, preservative, cosolvents and surfactants and/or cyclodextrin used as an excipient that may also enhance anti-viral properties.
SI is a condition that can lead to complete withdrawal from society, especially concerning the most fragile subgroups, such as youth and elderly populations. It is often a core (often prodromal) symptom of severe psychiatric disorders such as Hikikomori syndrome, social anxiety disorder, psychosis, depression, post-traumatic disorders stress disorder, obsessive-compulsive disorder, mood dysregulation, and autism spectrum disorders. If left untreated, SI can escalate into complete withdrawal from society. Therefore, early interventions for the treatment of SI could lead to a more favourable outcome for young patients. However, due to the social interaction barrier inherent to the condition, current treatments alone are problematic and only partially effective in treating SI. SOLITAIRE aims to implement a multi-component digital psychiatric intervention to help adolescents and young adults with SI based on CBT and/or CR for socially isolated participants and PE for their family members. All interventions will be delivered remotely, thus overcoming most of the barriers and limitations of standard face-to-face clinical interventions. In particular, a randomized controlled trial (RCT) will be conducted on participants with SI to test the feasibility and acceptability of the interventions and to evaluate the difference in efficacy between CBT+CR (experimental group) and CBT alone (control group). The CBT sessions will be audio-recorded. The recordings will then be analyzed using machine learning algorithms to build an automatic system for the evaluation of SI-related depressive symptoms starting from the voice. The digital interventions will last about 2-3 months. The investigators hypothesized that participants in the experimental group would show more durable and generalizable cognitive and behavioural improvements due to the neuroplasticity processes associated with CR. Furthermore, plasma samples of the socially isolated participants will be collected before and after the interventions and biochemically analyzed to explore the neurobiological basis of SI and treatment-related biomarkers.

Family members will be invited to undergo video calls with a psychotherapist (8 sessions, ≈1 hour/week) in which cognitive-behavioural and PE techniques will be combined to provide them with knowledge about the clinical aspects and treatments of SI. The content of the sessions will be adapted to the age and specific psychopathological profile of the socially isolated relatives.

Participants with SI can be included in the study even if their family members choose not to participate.
This herbal composition contains at least Folium or Tincture of Calendula and Folium or Tincture of Eucalyptus. In addition, it may contain Sucus of Plantain, Liquid Aloe extract and/or Vitaminized Rose Hip Syrup. The compositions have proved to be highly effective for the treatment or curing of diseases such as Virus Immunodefficiency, HIV-infections, AIDS, Viral Hepatitis, Tuberculosis (TBC), Meningitis and other virus or microbial etiology diseases in children and adults. Using it against these diseases, after only 20 to 30 days of treatment, dramatic improvements became evident, normalising blood sedimentation and its spectrum. Coughing disappears completely, perspiration and weakness is overcome, and the general condition of the patient is improved. The medication finds also application in oncological treatments for the improvement of the general condition and, most importantly, eliminates the very strong pain that characterizes such diseases. Since all components are totally harmless, they can be taken as a ointment to reinforce the entire organism against virus, microbia, etc., by both children or adults, without interfering with most other medications.
Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable. Concomitant use of succinylcholine has been associated with most, but not all, of these cases. These patients also experienced significant elevations in serum creatinine kinase levels and, in some cases, changes in urine consistent with myoglobinuria. Despite the similarity in presentation to malignant hyperthermia, none of these patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state. Early and aggressive intervention to treat the hyperkalemia and resistant arrhythmias is recommended, as is subsequent evaluation for latent neuromuscular disease.
PURPOSE: A reduction is provided to change the hair production rate, reduce the hair follicle and hair shaft sizes and further reduce the hair shaft pigmentation by topically applying a botanical extract, etc., having a serine protease inhibitory activity. CONSTITUTION: An effective amount of a topically active composition comprising one or more kinds of compounds derived from one or more kinds of botanical families Leguminosae, Solanaceae, Gramineae and Cucurbitaceae is topically applied to skin of a mammal. A topically active agent preferred for use in the composition includes a protease inhibitor (e.g. a soybean tryspin inhibitor) and a natural plant extract having the protease inhibitory activity (e.g. a soybean extract such as a soybean milk) and a mixture thereof. The protease inhibitor is preferably contained in an amount of 0.0001-20% (wt./vol.) and the plant extract is preferably contained in an amount of 10-99% (vol./vol.). The topical activator composition is preferably applied to the skin surface so as to be present at about 2-500 L/cm2 on the skin surface.
A computer system provides nutrition-based management of health conditions using machine learning. Health information of a user is evaluated to determine a health condition. Medication information for the user is analyzed and the medication information is mapped to the health condition. One or more natural treatments for the user are determined from information sources based on the mapped health condition and medication information, wherein the one or more natural treatments include one or more from a group of nutrition and mind/body treatments, and wherein the information sources include information from crowdsourcing. The one or more natural treatments and medication information for the health condition are indicated. Embodiments of the present invention further include a method and program product for providing nutrition-based management of health conditions using machine learning in substantially the same manner described above.
<P>PROBLEM TO BE SOLVED: To provide a dispersion stabilizer easy to disperse a hardly oil soluble component in an oily dispersing medium in a stable state, a dispersion liquid composition for use in filling a capsule easy to disperse the hardly oil soluble component in a stable state, a filling composition hard to cause the separation of respective components and a capsule agent.  <P>SOLUTION: The dispersion stabilizer comprises an L-ascorbic acid-fatty acid ester (A-P) and the dispersion liquid composition is obtained by mixing the dispersion stabilizer and the oily dispersing medium under stirring while heating them to a temperature being the melting point of the dispersion stabilizer or above. As the oily dispersing medium, vegetable oil is preferable. The filling composition contains the dispersion liquid composition and the hardly oil soluble component. The capsule agent is filled with the filling composition. The filling composition containing the dispersion stabilizer comprising A-P is extremely low in viscosity change as compared with a composition containing a conventional dispersant such as beeswax, a glycerine fatty acid ester, candelilla wax or the like.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.
BACKGROUND Carotid-cavernous fistula (CCF) is a rare, atypical vascular shunt between the carotid arterial system and the venous channels of the cavernous sinus, classified according to the shunt's anatomy, by etiology (resulting from trauma or occurring spontaneously), or by hemodynamic characteristics (such as low- or high-flow fistulas). CASE REPORT A 62-year-old female patient with poorly controlled arterial hypertension presented with bilateral periorbital edema, conjunctival chemosis, ophthalmoplegia, diplopia, and diminished visual acuity. On magnetic resonance angiography (MRA), abnormal arterial flow along the cavernous sinuses was noted, suggestive of bilateral CCF. The diagnosis of indirect dural low-flow CCF (Barrow Type D) was later confirmed by digital subtraction angiography, with feeding arteries from intracavernous internal carotid artery branches, and meningeal branches of the external carotid artery, draining bilaterally to ophthalmic veins, the intracavernous sinus, and the inferior petrosal sinus. The patient was successfully treated with endovascular embolization. At 7-month follow-up, no residual arteriovenous shunting was detected. This case highlights the importance of non-invasive radiological methods for CCF, and presents rarely published radiological findings of bilateral Type-D dural CCFs on 3-dimensional time-of-flight MRA with post-treatment MRA follow-up. CONCLUSIONS Regardless of the patient's history of possible trauma, a patient presenting with bilateral periorbital edema, conjunctival chemosis, ophthalmoplegia, diplopia, and diminished visual acuity should have a spontaneous bilateral CCF investigated to prevent delayed treatment. Experienced neuroradiologists are needed to accurately detect indirect CCF, since this condition often does not demonstrate classic symptoms.
The prevalence and incidence of obesity and the comorbidities linked to it are increasing worldwide. Current therapies for obesity and associated pathologies have proven to cause a broad number of adverse effects, and often, they are overpriced or not affordable for all patients. Among the alternatives currently available, natural bioactive compounds stand out. These are frequently contained in pharmaceutical presentations, nutraceutical products, supplements, or functional foods. The clinical evidence for these molecules is increasingly solid, among which epigallocatechin-3-gallate, ellagic acid, resveratrol, berberine, anthocyanins, probiotics, carotenoids, curcumin, silymarin, hydroxy citric acid, and α-lipoic acid stand out. The molecular mechanisms and signaling pathways of these molecules have been shown to interact with the endocrine, nervous, and gastroenteric systems. They can regulate the expression of multiple genes and proteins involved in starvation-satiety processes, activate the brown adipose tissue, decrease lipogenesis and inflammation, increase lipolysis, and improve insulin sensitivity. This review provides a comprehensive view of nature-based therapeutic options to address the increasing prevalence of obesity. It offers a valuable perspective for future research and subsequent clinical practice, addressing everything from the molecular, genetic, and physiological bases to the clinical study of bioactive compounds.
PCT No. PCT/EP94/00670 Sec. 371 Date Feb. 12, 1996 Sec. 102(e) Date Feb. 12, 1996 PCT Filed Mar. 7, 1994 PCT Pub. No. WO94/22481 PCT Pub. Date Oct. 13, 1994An active substance patch releasing estradiol to the skin is characterized by the fact that it consists essentially of a backing layer and an attached active substance reservoir which comprises pressure sensitive adhesive and in which the active substance is at least partially soluble, and of a removable protective layer covering the adhesive film, the active substance reservoir being a polymer matrix which-in order to improve the bioavailability of the estradiol-comprises an added penetration enhancer of the general formula:   <IMAGE>   wherein R=-CH2OH or -CH2-O-CH2-CHOH-CH2OH.
<P>PROBLEM TO BE SOLVED: To provide a composition for alleviating free radical toxicity, and a method for it.  <P>SOLUTION: This composition uses both a biocompatible polymer and a nitroxide. Especially, a red blood cell substitute is described and this is a stable nitroxide used for a hemoglobin solution containing no cell, an encapsulated hemoglobin solution, a polymerized hemoglobin solution, a composite hemoglobin solution, a nitroxide-labeled albumin, and a nitroxide-labeled immune globulin. This preparation acts in an antioxidative enzyme mode holding the nitroxide in an active form in vivo and shows a mutual action with a free radical. Its use includes a blood substitute, a radiation protective agent, an imaging agent, a protectant for ischemia and reperfusion injury, and an in vivo enzyme mode in illnesses, especially in brain ischemia of apoplexy.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PURPOSE:To prepare the titled composition having remarkably improved stability of prostaglandin compounds and exhibiting various pharmacological activities such as thrombocyte coagulation inhibiting action, hypotensive action, etc., by dissolving a prostaglandin compound such as 5-thiaprostaglandin E1, etc., in a vegetable oil. CONSTITUTION:The objective prostaglandin preparation composition can be prepared by dissolving one or more compounds selected from 5-thiaprostaglandin E1, 6-nitroprostaglandin E1, 7-halogenated prostaglandin I2, 9(0)-methanoprosta glandin I1 and 15-deoxy-16-hydroxy-7-thiaprostaglandin E1 in a vegetable oil (e.g. coconut oil). It has been difficult to produce a drug preparation of prosta glandin compound because of its poor stability. The stability can be improved by the use of generally 100-200,000pts.wt. of vegetable oil per 1pt. of the com pound, and the prostaglandin compound can be used as a drug in the form of oral drug, suppository, transcutaneous drug, injection, etc.
A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Transfusion of Orthopaedic trauma patients is routinely done in asymptomatic individuals as there is no accepted national standard or recommendations from the American Academy of Orthopaedic Surgeons or the Orthopaedic Trauma Association for what level of anemia is appropriate in an asymptomatic patient. Individual practitioners typically make this decision based on anecdotal experiences and expert opinion. No prospective study has been performed to date to answer this question in this patient population.

The null hypothesis of this proposed pilot study is that no difference will be seen with a liberal transfusion strategy to keep a patient's hemoglobin above 7 g/dL versus a conservative strategy to keep the patient's hemoglobin above 5.5 g/dL in patients asymptomatic at rest. The primary outcome of this pilot study will be infection; defined as postoperative wound infection (superficial or deep) or other perioperative infection but not surgical site (urinary tract infection or pneumonia). Deep infection is defined as the need for intravenous antibiotics or a return to surgery for debridement. Superficial infection is defined as the use of oral antibiotics only successfully treat a surgical site infection. Secondary outcomes will include pulmonary embolism, deep venous thrombosis, acute renal failure or insufficiency, nonunion, delayed union, compartment syndrome, osteomyelitis, nerve palsy, anoxic brain injury, cardiac ischemia or infarct, pancreatitis, or death, and the musculoskeletal functional assessment.
PROBLEM TO BE SOLVED: To provide a wave generating device where a frequency for generating wave is a variable type and high precision for frequency is not required in the device for generating wave by which skin conductive route electric conduction is adjusted. SOLUTION: Medicine cases 4-7 having a tunnel part, their lids, cotton, filters, a lens, a cylinder and glass wool are fixed inside the cylinder consisting of the three-layer structure of the cylinder 1, a wave adjusting substance layer 2 and the cylinder 3. A disk with a hole is fixed to the upper part of glass wool. A sonic wave generator is fixed on a circular bottom plate. A signal with a variable frequency from an oscillator is amplified and inputted to the electrode of the sonic wave generator and sonic wave is generated so as to pass through the tunnel parts of the medicine cases. A coil is wound around the cylinder 1, the cylinder 2 and one or some of the medicine cases and the direction of its magnetic field is adopted as the sonic wave propagating direction.
The group receives 3 sessions of ultrasound-guided percutaneous neuromodulation. The sessions wil be received at day 1, 7 and 14 of the study.
Frailty is a complex, age-related clinical condition that involves multiple contributing factors and raises the risk of adverse outcomes in older people. Given global population ageing trends, the growing prevalence and incidence of frailty pose significant challenges to health and social care systems in both high-income and lower-income countries. In this review, we highlight the disproportionate representation of research on frailty screening and management from high-income countries, despite how lower-income countries are projected to have a larger share of older people aged ≥60. However, more frailty research has been emerging from lower-income countries in recent years, paving the way for more context-specific guidelines and studies that validate frailty assessment tools and evaluate frailty interventions in the population. We then present further considerations for contextualising frailty in research and practice in lower-income countries. First, the heterogeneous manifestations of frailty call for research that reflects different geographies, populations, health systems, community settings and policy priorities; this can be driven by supportive collaborative systems between high-income and lower-income countries. Second, the global narrative around frailty and ageing needs re-evaluation, given the negative connotations linked with frailty and the introduction of intrinsic capacity by the World Health Organization as a measure of functional reserves throughout the life course. Finally, the social determinants of health as possible risk factors for frailty in lower-income countries and global majority populations, and potential socioeconomic threats of frailty to national economies warrant proactive frailty screening in these populations.
AIMS: To develop a scale to assess difficulties that nurses experience when collaborating with physicians in responding to clinical deterioration during night shifts and identify factors associated with scoring using the developed scale.
METHODS: A web-based questionnaire with a draft scale, the Nighttime Collaboration Difficulties between Nurses and Physicians for Nurses (NCDNP-N), was distributed to nurses working night shifts in acute-care hospitals across Japan. Data were collected between July and October 2023. Of 435 responses, 405 were examined for the NCDNP-N's psychometric validation, including structural validity, criterion-related validity, and reliability assessments. Multiple linear regression analysis was performed for 385 responses excluded by listwise methods to identify factors associated with NCDNP-N scores.
RESULTS: The NCDNP-N has 10 items and three domains: Domain 1, dissatisfaction with physicians' actions; Domain 2, burden of working with night-shift physicians; and Domain 3, barriers to reporting during night shifts. Estimated reliability coefficients exceeded the recommended values. Multiple regression analyses demonstrated that more years of experience in the current ward and frequency of calling the covering physician at night were markedly associated with higher scores, whereas more nursing experience was associated with lower scores.
CONCLUSION: We developed the NCDNP-N and confirmed its validity and reliability. The study results suggest that the responsibilities and competence of nurses working night shifts and communication with the night-covering physician are associated with difficulties in nighttime collaboration. The NCDNP-N may help identify challenges in clinical settings as well as can be utilized in the evaluation study for improving nighttime collaboration.
One group of participants are under observation. This trial has two phase. Phase I: 40 participants will be enrolled. Only if epigenetic cfDNA library has been built, investigators would move on to Phase II. Another 60 participants will be enrolled for further analysis.
While inpatient during the postpartum period, patients will be identified who were diagnosed with hypertensive disorders of pregnancy antepartum, intrapartum, or postpartum. These patients will be recruited prior to discharge home. This will be a randomized control trial, non-blinded. The study group will receive a mobile app for postpartum education and an integrated Wi-Fi connected blood pressure cuff for at-home monitoring for 16 days postpartum. The home BP monitoring will occur twice a day and study team will check the BPs twice a day and intervene by phone or text if necessary. The control group will be scheduled for blood pressure checks at the clinic between days 7-10. These groups will be compared with regard to adherence to guidelines from the American College of Obstetricians and Gynecologists for blood pressure monitoring, antihypertensive initiation after discharge, unscheduled visits, readmission, and attendance of postpartum visit.